CrossRoads Extremity Systems Acquires Multiple Implant Systems from Surgical Frontiers

CrossRoads Extremity Systems acquired a range of FDA-cleared technology assets from Surgical Frontiers. The add-on acquisition furthers CrossRoads’ strategy to grow its presence in the orthopedic extremities sector. Transaction details were not disclosed.

The transaction includes:

• The KATOR® family of soft tissue-to-bone reattachment products for Achilles tendon repair, ligament stabilization, and arthroscopic rotator cuff repair
• OsteoPrecise™ precision cutting guides for bone alignment in small bone osteotomies and fusions
• The SpeedButton™ for anatomic ligament reattachment with strong pull-out strength and a better ligament footprint
• The Metrics portfolio for the precise, reproducible restoration of anatomic bone alignment and ligament function in high ankle sprains and ankle fractures

The acquired assets are covered by a total of 16 issued and 10 pending U.S. patents. These products were developed under the umbrella of Surgical Frontiers, which collaborates on the development of clinically-ready technologies for sale to exiting medical device companies for their commercialization.

CrossRoads is a Fund IV portfolio company of private equity firm HealthpointCapital, which invested in CrossRoads Extremity Systems in 2019. CrossRoads’ Active Stabilization® technology supports fusion through continuous dynamic compression and enhances stability through a hybrid construct of a nitinol staple within a fixation plate. Further, the company’s reusable instrumentation and EcoSMART® instrument recovery program promote efficient inventory management and improved economics for healthcare facilities.

“As we continue on our fast-growth trajectory, we are excited to add to our portfolio a range of technologies that have significant advantages over the current standard of care,” said Vernon Hartdegen, CEO and Co-Founder of CrossRoads. “These unique and highly complementary technologies and intellectual property will further round out our product portfolio and drive cross-selling opportunities. The acquisition is perfectly aligned with our philosophy of offering less-invasive surgical solutions centered on better outcomes for the patient and ease of use for the surgeon.”